Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azetukalner in Moderate-to-Severe Major Depressive Disorder
NCT07076407Phase 3Active, not recruiting
- Sponsor
- Xenon Pharmaceuticals
- Start
- Jul 2025
- Primary completion
- May 2027
- Modality
- Small Molecules
- Countries
- 7
01
Overview
A Phase 3 trial of azetukalner in major depressive disorder (MDD), sponsored by Xenon Pharmaceuticals. Started Jul 2025; status: active, not recruiting.
02
Drugs
azetukalner
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT07076407.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07076407.